Scarica l'app Stockscreener
3.08
5.00%
-0.12
Dopo l'orario di chiusura:
3.10
0.02
+0.65%
Precedente Chiudi:
$3.20
Aprire:
$3.16
Volume 24 ore:
180.63K
Relative Volume:
0.19
Capitalizzazione di mercato:
$24.85M
Reddito:
-
Utile/perdita netta:
$-21.79M
Rapporto P/E:
-0.4981
EPS:
-6.1838
Flusso di cassa netto:
$-23.12M
1 W Prestazione:
-0.65%
1M Prestazione:
+10.14%
6M Prestazione:
-11.88%
1 anno Prestazione:
+1,120%
Intervallo 1D:
$3.02
$3.29
Intervallo di 1 settimana:
$2.97
$3.29
Portata 52W:
$0.241
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Nome
Cellectar Biosciences Inc
Settore
Industria
Telefono
(608) 441-8120
Indirizzo
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.11 | 25.57M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-12-05 | Ripresa | Ladenburg Thalmann | Buy |
| 2020-07-01 | Iniziato | Oppenheimer | Outperform |
| 2020-01-21 | Ripresa | ROTH Capital | Buy |
| 2019-09-13 | Iniziato | ROTH Capital | Buy |
| 2016-12-21 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences Announces Board Changes and New Director - TipRanks
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart
Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent
What's Going With Cellectar Biosciences Stock On Wednesday? - MSN
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks
Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK
Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus
Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria
CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView
Cellectar (CLRB) Secures $140 Million Financing for Regulatory M - GuruFocus
Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call - Benzinga
Cellectar Biosciences 1Q Loss $5.65M >CLRB - Moomoo
CLRB: Strong efficacy in r/r WM and robust financing position clinical programs for key milestones - TradingView
Cellectar Biosciences reports Q1 2026 net loss of $5.65M; cash $8.3M before $31M financing - TradingView
Cellectar Biosciences (CLRB) posts Q1 2026 loss and secures up to $140M - Stock Titan
Cellectar Biosciences, Inc. Q1 2026: Net loss $(5.65M), EPS $(1.33) — 10-Q Summary - TradingView
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cellectar Biosciences (NASDAQ: CLRB) posts Q1 loss and flags going-concern risk - Stock Titan
CLRB: Net loss narrowed, clinical data for iopofosine I 131 remained strong, and $35M was raised for Phase 3 - TradingView
Cellectar Biosciences Inc expected to post a loss of $1.88 a shareEarnings Preview - TradingView
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock - Investing.com UK
Cellectar Biosciences CEO buys $24,998 in company stock By Investing.com - Investing.com South Africa
Cellectar Biosciences COO Jarrod Longcor buys $24,998 in stock By Investing.com - Investing.com Canada
Cellectar (NASDAQ: CLRB) COO boosts stake with common stock and warrant buys - Stock Titan
Cellectar (CLRB) CEO reports open-market stock and warrant buys - Stock Titan
Stonepine, Jon Plexico disclosed 9.9% stake in Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 - Investing News Network
Cellectar Biosciences Inc Azioni (CLRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cellectar Biosciences Inc Azioni (CLRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
May 07 '26 |
Buy |
2.88 |
8,680 |
24,998 |
20,318 |
| NEIS JOHN | Director |
Dec 12 '25 |
Sale |
3.70 |
198 |
732 |
10 |
| CARUSO JAMES V | Chief Executive Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
11,638 |
| Longcor Jarrod | Chief Operating Officer |
Jul 02 '25 |
Buy |
4.99 |
10,000 |
49,900 |
12,768 |
| Kolean Chad J | Chief Financial Officer |
Jul 02 '25 |
Buy |
4.99 |
5,000 |
24,950 |
6,418 |
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):